|Table of Contents|

The role and mechanism of GDF15 in tumor bone metastases

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
674-677
Research Field:
Publishing date:

Info

Title:
The role and mechanism of GDF15 in tumor bone metastases
Author(s):
Duan Lian1; Pang Hailin1; Chen Wenjuan2; Cao Peipei1; Zhang Helong1; 3
1.Department of Oncology,Tangdu Hospital,Air Force Medical University，Shaanxi Xi'an 710038,China;2.Department of Oncology,Shaanxi Province Tumor Hospital，Shaanxi Xi'an 710061,China;3.Tangdu Comprehensive Cancer Center,Tangdu Hospital,Air Force Medical Uni
Keywords:
GDF15; tumor; bone metastases
PACS:
R738.1
DOI:
10.3969/j.issn.1672-4992.2019.04.034
Abstract:
Patients with malignant tumors often die of complications caused by tumor metastases rather than primary lesions.People in China often have a weak awareness of preventing cancer.A large number of patients are at the advanced stage of the tumor at the time of treatment,so the mortality rate of malignant tumors continues to rise.Tumors often metastasize to bone tissue,once bone metastases occur,complications such as SREs will severely reduce the quality of life of patients.However,at this stage,the level of diagnosis and treatment of tumor bone metastases is very limited,and the relevant mechanism is less known.The role of GDF15 in tumors has been recognizedgradually,and it has also been reported in several bone-related diseases including bone metastases.Therefore,GDF15 is very likely to play an important role in tumor bone metastasis.This article will review the controversial role and mechanism of GDF15 in bone metastases and related diseases of tumors.

References:

［1］ Yang L,Du S.Efficacy and safety of zledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis:A Meta-analysis［J］.Medicine (Baltimore),2015,94(42):e1822.
［2］ Silva SC,Wilson C,Woll PJ.Bone-targeted agents in the treatment of lung cancer［J］.Ther Adv Med Oncol,2015,7(4):219-228.
［3］ Winter MC,Coleman RE.Bisphosphonates in the adjuvant treatment of breast cancer［J］.Clinical Oncology,2013,25(2):135-145.
［4］Corre J,Hebraud B,Bourin P.Concise review:Growth differentiation factor 15 in pathology:A clinical role［J］?Stem Cells Transl Med,2013,2(12):946-952.
［5］ Li C,Wang X,Casal I,et al.Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer［J］.J Cell Mol Med,2016,20(8):1420-1426.
［6］ Liu X,Chi X,Gong Q,et al.Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma［J］.PLoS One,2015,10(5):e127518.
［7］ Brown DA,Hance KW,Rogers CJ,et al.Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15):a potential screening tool for the prevention of colon cancer［J］?Cancer Epidemiol Biomarkers Prev,2012,21(2):337-346.
［8］ Wollert KC,Kempf T,Wallentin L.Growth differentiation factor 15 as a biomarker in cardiovascular disease［J］.Clin Chem,2017,63(1):140-151.
［9］ Berezin AE.Diabetes mellitus related biomarker:The predictive role of growth-differentiation factor-15［J］.Diabetes Metab Syndr,2016,10(1 Suppl 1):S154-S157.
［10］ Lipton A.Toward new horizons:the future of bisphosphonate therapy［J］.Oncologist,2004,9(Suppl 4):38-47.
［11］ Michaelson MD,Smith MR.Bisphosphonates for treatment and prevention of bone metastases［J］.J Clin Oncol,2005,23(32):8219-8224.
［12］ Coleman R.On the horizon:Can bisphosphonates prevent bone metastases［J］?The Breast,2007,16:21-27.
［13］ Coleman R,Cameron D,Dodwell D,et al.Adjuvant zoledronic acid in patients with early breast cancer:final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial［J］.The Lancet Oncology,2014,15(9):997-1006.
［14］ Ottewell PD,Wang N,Brown HK,et al.Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo［J］.Clin Cancer Res,2014,20(11):2922-2932.
［15］ Stopeck AT,Lipton A,Body JJ,et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,double-blind study［J］.J Clin Oncol,2010,28(35):5132-5139.
［16］ Wang X,Baek SJ,Eling TE.The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer［J］.Biochem Pharmacol,2013,85(5):597-606.
［17］ Hromas R,Hufford M,Sutton J,et al.PLAB,a novel placental bone morphogenetic protein［J］.Biochim Biophys Acta,1997,1354(1):40-44.
［18］ Westhrin M,Moen SH,Holien T,et al.Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease［J］.Haematologica,2015,100(12):e511-e514.
［19］ Wakchoure S,Swain TM,Hentunen TA,et al.Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss［J］.Prostate,2009,69(6):652-661.
［20］ Windrichova J,Fuchsova R,Kucera R,et al.Testing of a novel cancer metastatic multiplex panel for the detection of bone-metastatic disease-a pilot study［J］.Anticancer Res,2016,36(4):1973-1978.
［21］ Windrichova J,Fuchsova R,Kucera R,et al.MIC1/GDF15 as a bone metastatic disease biomarker［J］.Anticancer Res,2017,37(3):1501-1505.
［22］ Corre J,Labat E,Espagnolle N,et al.Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma［J］.Cancer Res,2012,72(6):1395-1406.
［23］Duan Lian,Pang Hailin,Cai Yanfei,et al.The effect of overexpression of GDF15 on the biological behavior of lung adenocarcinomacell A549［J］.Modern Oncology,2018,26(7):984-988.［段炼，庞海林，蔡燕飞，等.过表达GDF15对肺腺癌细胞A549增殖、迁移和侵袭能力的影响［J］.现代肿瘤医学，2018,26(7):984-988.］
［24］ Zhang Y,Jiang W,Wang L,et al.Sex-specific differences in the modulation of growth differentiation factor 15 (GDF15) by hyperoxia in vivo and in vitro:Role of Hif-1alpha［J］.Toxicol Appl Pharmacol,2017,332:8-14.
［25］ Bertrand C,Kowalski-Chauvel A,Do C,et al.A gastrin precursor,gastrin-gly,upregulates VEGF expression in colonic epithelial cells through an HIF-1-independent mechanism［J］.Int J Cancer,2010,126(12):2847-2857.
［26］ Maroni P,Matteucci E,Luzzati A,et al.Nuclear co-localization and functional interaction of COX-2 and HIF-1alpha characterize bone metastasis of human breast carcinoma［J］.Breast Cancer Res Treat,2011,129(2):433-450.
［27］ Li C,Wang J,Kong J,et al.GDF15 promotes EMT and metastasis in colorectal cancer［J］.Oncotarget,2016,7(1):860-872.
［28］ Min KW,Liggett JL,Silva G,et al.NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway［J］.Oncogene,2016,35(3):377-388.
［29］ Kim KK,Lee JJ,Yang Y,et al.Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells［J］.Carcinogenesis,2008,29(4):704-712.
［30］ Osada M,Park HL,Park MJ,et al.A p53-type response element in the GDF15 promoter confers high specificity for p53 activation［J］.BiochemBiophys Res Commun,2007,354(4):913-918.
［31］ Lee SH,Krisanapun C,Baek SJ.NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta,C/EBPbeta and ATF3［J］.Carcinogenesis,2010,31(4):719-728.
［32］ Baek SJ,Kim JS,Moore SM,et al.Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1,which results in the up-regulation of NAG-1,an antitumorigenic protein［J］.Mol Pharmacol,2005,67(2):356-364.
［33］ Vaňhara P,Lincová E,Kozubík A,et al.Growth/differentiation factor-15 inhibits differentiation into osteoclasts-A novel factor involved in control of osteoclast differentiation［J］.Research in Biological Diversity,2009,78(4):213-222.
［34］ Wakchoure S,Swain TM,Hentunen TA,et al.Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss［J］.Prostate,2009,69(6):652-661.

Memo

Memo:
National Natural Science Foundation of China(No.81572251);国家自然科学基金资助项目（编号：81572251）
Last Update: 1900-01-01